Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2023 Feb;95(2):e28452.
doi: 10.1002/jmv.28452.

Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation-related hepatitis

Goki Suda  1 , Masaru Baba  2 , Yoshiya Yamamoto  3 , Takuya Sho  1 , Koji Ogawa  1 , Megumi Kimura  1 , Shunichi Hosoda  1 , Sonoe Yoshida  1 , Akinori Kubo  1 , Qingjie Fu  1 , Zijian Yang  1 , Yoshimasa Tokuchi  1 , Takashi Kitagataya  1 , Osamu Maehara  4 , Shunsuke Ohnishi  4 , Ren Yamada  1 , Masatsugu Ohara  1 , Naoki Kawagishi  1 , Mitsuteru Natsuizaka  1 , Masato Nakai  1 , Kenichi Morikawa  1 , Ken Furuya  2 , Kazuharu Suzuki  1   3 , Takaaki Izumi  5 , Takashi Meguro  6 , Katsumi Terashita  7 , Jun Ito  8 , Tomoe Kobayashi  9 , Izumi Tsunematsu  10 , Naoya Sakamoto  1
Affiliations
Multicenter Study

Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation-related hepatitis

Goki Suda et al. J Med Virol. 2023 Feb.

Abstract

No prospective study on the efficacy of tenofovir alafenamide (TAF), a novel tenofovir prodrug, in preventing hepatitis B virus (HBV) reactivation has yet been reported. This multicenter prospective study enrolled HBV-carriers who received TAF to prevent HBV reactivation before antitumor or immunosuppressive therapy, and patients with resolved HBV infection who experienced HBV-reactivation and received TAF to prevent HBV reactivation-related hepatitis. The efficacy of prophylactic TAF in preventing HBV reactivation and HBV reactivation-related hepatitis was evaluated at 6 and 12 months after initiating TAF. Overall, 110 patients were administered TAF to prevent HBV reactivation or HBV reactivation-related hepatitis. Three patients died owing to primary disease, whereas one patient was transferred to another hospital within 6 months after initiating TAF. Seven patients died due to primary disease, and five patients were transferred to another hospital within 12 months after initiating TAF. Therefore, 106 and 94 (77 patients with HBV infection, 17 with previous-HBV infection) patients were evaluated at 6 and 12 months after initiating TAF, respectively. No patient experienced HBV reactivation, HBV reactivation-related hepatitis, or treatment discontinuation due to HBV reactivation or adverse events of TAF after 6 and 12 months. TAF could effectively prevent HBV reactivation and HBV reactivation-related hepatitis.

Keywords: HBV infection; chemotherapy disruption; immunosuppressive therapy; prevention; prophylactic administration; prospective multicenter study; tenofovir alafenamide.

PubMed Disclaimer

References

REFERENCES

    1. Organization WH Fact Sheet: Hepatitis B. 2021.
    1. Drafting Committee for Hepatitis Management Guidelines tJSoH. Japan Society of Hepatology Guidelines for the management of hepatitis B virus infection: 2019 update. Hepatol Res. 2020;50(8):892-923.
    1. Di Bisceglie AM, Lok AS, Martin P, Terrault N, Perrillo RP, Hoofnagle JH. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology. 2015;61(2):703-711.
    1. Umemura T, Tanaka E, Kiyosawa K, Kumada H. Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan. Clin Infect Dis. 2008;47(5):e52-e56.
    1. Hui CK, Cheung WWW, Zhang HY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology. 2006;131(1):59-68.

Publication types

LinkOut - more resources